GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLA) » Definitions » Debt-to-EBITDA

ESLA (Estrella Immunopharma) Debt-to-EBITDA : 0.00 (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Estrella Immunopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.00 Mil. Estrella Immunopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.00 Mil. Estrella Immunopharma's annualized EBITDA for the quarter that ended in Jun. 2024 was $-15.80 Mil. Estrella Immunopharma's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Estrella Immunopharma's Debt-to-EBITDA or its related term are showing as below:

ESLA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.04   Med: 0   Max: 0
Current: -0.04

ESLA's Debt-to-EBITDA is ranked worse than
100% of 269 companies
in the Biotechnology industry
Industry Median: 1.5 vs ESLA: -0.04

Estrella Immunopharma Debt-to-EBITDA Historical Data

The historical data trend for Estrella Immunopharma's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma Debt-to-EBITDA Chart

Estrella Immunopharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Debt-to-EBITDA
- - - -

Estrella Immunopharma Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.04 - - -

Competitive Comparison of Estrella Immunopharma's Debt-to-EBITDA

For the Biotechnology subindustry, Estrella Immunopharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Estrella Immunopharma's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Estrella Immunopharma's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Estrella Immunopharma's Debt-to-EBITDA falls into.



Estrella Immunopharma Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Estrella Immunopharma's Debt-to-EBITDA for the fiscal year that ended in Jun. 2024 is calculated as

Estrella Immunopharma's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -15.796
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2024) EBITDA data.


Estrella Immunopharma  (NAS:ESLA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Estrella Immunopharma Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Estrella Immunopharma Business Description

Traded in Other Exchanges
N/A
Address
5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608
Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma Headlines